Evotec Licenses CRISPR Tech From Broad Institute, Harvard

Jul 06, 2016 | a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – Evotec announced today that it has acquired a non-exclusive license to CRISPR-Cas9 genome-editing technology from the Broad Institute and Harvard University.

Under the terms of the deal, Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification, as well as to strengthen its post-phenotypical screening target deconvolution platform.

Additional terms of the arrangement were not disclosed.

The Broad — a partnership between Harvard and the Massachusetts Institute of Technology — has issued a number of licenses to its CRISPR-Cas9 technology recently, including ones to ATCC, Transposagen, GE Healthcare, and Sigma-Aldrich.

Filed Under Business News | Gene Silencing/Gene Editing | licensing agreement | Broad Institute | Harvard | CRISPR | Evotec

Related Articles

Nov 24, 2015
Regeneron Licenses CRISPR-Cas9 IP From ERS Genomics

Sep 22, 2016
Monsanto Licenses CRISPR From Broad Institute for Ag-Bio Applications

Jan 12, 2016
ATCC Licenses CRISPR/Cas9 Tech From Broad Institute

Dec 11, 2015

Broad Institute Licenses CRISPR/Cas9 IP to Transposagen

Aug 08, 2016

Non-CRISPR Genome-Editing Technologies Find Niche in Biotech Applications ■

Aug 23, 2016

Broad Institute Licenses CRISPR/Cas9 to AMRI

We recommend

Broad Institute Licenses CRISPR/Cas9 to AMRI
GenomeWeb, 2016

Horizon Expands CRISPR-Cas9 Portfolio with Broad Institute Licensing Deal
GenomeWeb, 2014

Broad Licenses CRISPR/Cas9 IP to GE Healthcare, Sigma-Aldrich
GenomeWeb, 2014

Sage Licenses CRISPR-Cas9 Technology from Broad Institute
GenomeWeb, 2014

Clontech Licenses CRISPR-Cas9 Technology from Broad Institute
GenomeWeb, 2014

Editas Licenses Engineered Cas9 Variants From MGH
GenomeWeb, 2016

Powered by TrendMD

Privacy Policy. Copyright © 2016 Genomeweb LLC. All Rights Reserved.